A new method to deliver drugs for Alzheimer's disease treatment.
Official title: A smart cell drug (SmaCD) delivery platform for mobile, targetable, and self-regulated combination therapy: a model project to rescue antibodies from Alzheimer's disease (AD) clinical trial failures
Funded at Buck Institute for Research on Aging · NIH-10873903 · Data updated 2026-11-12
This study is exploring a new way to deliver medications for Alzheimer's disease that could make treatments work better by targeting different aspects of the condition, so patients might have a more effective option for managing their symptoms.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Buck Institute for Research on Aging NIH-funded |
| Lab location | 1 site (Novato, United States) |
| Project start | September 1, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $476,782 |
| NIH project number | 5R01AG081989-03 |
| Project ID | NIH-10873903 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with Alzheimer's disease, particularly those in the early to moderate stages of the condition.
✕Less likely to help
Patients with advanced Alzheimer's disease or those who do not have a confirmed diagnosis may not benefit from this research.
What this research studies
This research investigates a novel smart cell drug delivery platform designed to improve the effectiveness of combination therapies for Alzheimer's disease. By focusing on multiple pathological components of the disease, including amyloid beta, tau pathology, and gliosis, the approach aims to enhance treatment outcomes. The methodology involves using a smart cell-based system that can target and regulate drug delivery, potentially overcoming the limitations of current therapies. Patients may benefit from a more effective treatment strategy that addresses the complexities of Alzheimer's disease.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Alzheimer's disease, improving patient outcomes and quality of life.
How similar studies have gone: While combination therapies for Alzheimer's have been explored, this specific smart cell delivery approach is relatively novel and has not been widely tested in clinical settings.
Where this research is happening
-
Buck Institute for Research on Aging
Novato, United States Active
Researchers
- Principal investigator: Andersen, Julie Kay — Buck Institute for Research on Aging
- Study coordinator: Andersen, Julie Kay
Related research
Other NIH-funded projects on the same topics.
-
Alzheimer’s disease and related brain changes linked to chemicals in the body
This NIH grant supports a patient-centered effort to map how environmental exposures and body chemistry relate to Alzheimer’s disease and related dementias.
-
Understanding how everyday exposures affect Alzheimer's disease progression
A national research effort is studying how environmental exposures, gut health, diet, and metabolism relate to Alzheimer's and related dementias to identify new ways to diagnose and treat these conditions.
-
How environment, gut health, and metabolism affect Alzheimer’s disease
This grant looks at how environmental exposures, gut microbes, diet, and metabolism influence Alzheimer’s disease and related dementias.
-
Understanding how chemical exposures affect Alzheimer's disease progression
This project studies how environmental chemicals and other biological factors influence brain health and the course of Alzheimer’s disease and related dementias.
-
Understanding how brain hyperexcitability and sex differences affect Alzheimer’s disease
This grant tests whether brain hyperexcitability linked to a genetic risk (APOE4) and sex differences contribute to memory decline in Alzheimer’s disease, using computer simulations and mouse data to guide potential human treatments.
-
CNS Exosomes and Adaptive Immunity in Alzheimer’s Disease
This project studies how tiny brain vesicles called exosomes may activate the body's immune system in Alzheimer’s disease, with the goal of understanding mechanisms that could lead to new treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.